CINECA IRIS Institutional Research Information System

ROSSINI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.553
EU - Europa 716
AS - Asia 206
AF - Africa 55
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
SA - Sud America 1
Totale 2.533
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.529
IT - Italia 270
SE - Svezia 112
DE - Germania 96
CN - Cina 87
BG - Bulgaria 80
GB - Regno Unito 67
SG - Singapore 64
FR - Francia 44
CI - Costa d'Avorio 37
VN - Vietnam 32
CA - Canada 24
NG - Nigeria 11
FI - Finlandia 10
HK - Hong Kong 10
RU - Federazione Russa 10
PL - Polonia 9
IN - India 6
SN - Senegal 6
NL - Olanda 4
UA - Ucraina 4
ES - Italia 3
JP - Giappone 2
LV - Lettonia 2
AT - Austria 1
AU - Australia 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
EU - Europa 1
IE - Irlanda 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
MY - Malesia 1
RO - Romania 1
TR - Turchia 1
Totale 2.533
Salva come PNG Salva come JPEG
Città #
Fairfield 221
Woodbridge 202
Chandler 126
Houston 118
Seattle 101
Wilmington 94
Ashburn 87
Cambridge 85
Sofia 80
Ann Arbor 72
New York 68
Florence 49
Abidjan 37
Princeton 37
Lawrence 36
Pisa 32
Beijing 25
Medford 25
Milan 24
London 23
Serra 23
Ottawa 22
Dearborn 19
Bremen 18
Seacroft 18
Des Moines 16
Rome 15
Genoa 13
Lancaster 13
Nanjing 12
Lagos 11
San Diego 10
Verona 10
Warsaw 9
Dong Ket 8
Hong Kong 8
Kent 8
Los Angeles 8
Boulder 7
Kunming 7
Redwood City 7
Dakar 6
Hefei 6
Turin 6
Düsseldorf 5
Positano 5
Chicago 4
Hebei 4
Nanchang 4
Phoenix 4
Polverigi 4
Changsha 3
Jinan 3
Ogden 3
Singapore 3
Anzio 2
Bari 2
Berlin 2
Center 2
Dallas 2
Fano 2
Frankfurt am Main 2
Guangzhou 2
Marseille 2
Moscow 2
Norwalk 2
Noventa di Piave 2
Paris 2
Pistoia 2
Riga 2
Salerno 2
San Giuliano Terme 2
Santa Maria A Monte 2
Shanghai 2
Vitry-sur-seine 2
Almaty 1
Aprilia 1
Barcelona 1
Barnsley 1
Bellinzago Novarese 1
Berlingo 1
Bracknell 1
Buffalo 1
Cairo 1
Canelli 1
Castiglione Chiavarese 1
Catania 1
Central 1
Chengdu 1
Città della Pieve 1
Cologne 1
Council Bluffs 1
Figline Valdarno 1
Fiumefreddo Di Sicilia 1
Frattamaggiore 1
Fuzhou 1
Gallarate 1
Hanoi 1
Indiana 1
Indore 1
Totale 1.929
Salva come PNG Salva come JPEG
Nome #
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 151
TAS-102 for the treatment of metastatic colorectal cancer 130
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 105
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 105
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 101
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 99
null 98
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 93
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 92
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 87
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 86
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 85
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 79
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 76
A still missing piece of the FIRE-3 puzzle 75
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 74
null 69
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 67
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 62
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 60
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 60
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program 59
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 55
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 54
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study 52
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 46
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 42
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 42
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 38
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 37
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 35
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib 35
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 35
Individual patient data meta-analysis of folfoxiri plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer 30
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 27
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 23
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 23
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 21
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 18
TRIBE2 results and toxicity – Authors' reply 18
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 17
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 17
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 14
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 11
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 10
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 10
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 7
Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence 6
KDR genetic predictor of toxicities induced by sorafenib and regorafenib 6
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 3
TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply 3
Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy 2
Merkel cell carcinoma of the retroperitoneum with no identifiable primary site 1
Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC 1
Totale 2.652
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.272
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.272
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201993 0 0 0 0 0 0 0 0 0 0 52 41
2019/2020549 64 58 28 39 59 69 59 51 51 35 28 8
2020/2021343 12 16 9 15 5 81 32 19 55 17 24 58
2021/2022317 4 4 7 5 58 56 4 10 18 37 24 90
2022/2023529 51 75 38 36 46 51 28 30 92 2 70 10
2023/2024370 19 37 61 36 63 60 29 20 9 15 21 0
Totale 2.652